Capital Advisors Inc. OK Raises Stock Position in AbbVie Inc. $ABBV

Key Points

• Capital Advisors Inc. OK increased its AbbVie stake by 11.2% in the second quarter, adding 45,132 shares to own 447,129 shares valued at approximately $112.5 million. Institutional investors collectively own 70.23% of AbbVie.
• Analysts maintain a favorable outlook, with AbbVie receiving a consensus “Moderate Buy” rating and an average price target of $275.73; recent targets range as high as $298.
• AbbVie exceeded quarterly earnings and revenue expectations, reporting $3.65 in EPS and $16.99 billion in revenue, while its quarterly dividend of $1.73 represents a 2.8% annualized yield.

Capital Advisors Inc. OK grew its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 11.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 447,129 shares of the company's stock after purchasing an additional 45,132 shares during the quarter. AbbVie comprises about 1.7% of Capital Advisors Inc. OK's holdings, making the stock its 11th biggest holding. Capital Advisors Inc. OK's holdings in AbbVie were worth $112,516,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently modified their holdings of the company. Litman Gregory Wealth Management LLC bought a new position in AbbVie in the fourth quarter worth about $28,000. Imprint Wealth LLC boosted its position in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after acquiring an additional 45 shares in the last quarter. Legacy Wealth Managment LLC ID boosted its position in AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock valued at $31,000 after acquiring an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. purchased a new position in shares of AbbVie during the 4th quarter worth approximately $31,000. Finally, Abound Financial LLC purchased a new position in shares of AbbVie during the 4th quarter worth approximately $32,000. Institutional investors own 70.23% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ABBV. JPMorgan Chase & Co. raised their target price on AbbVie from $260.00 to $280.00 and gave the company an "overweight" rating in a research note on Thursday, July 9th. Evercore set a $235.00 price target on AbbVie in a research note on Friday, May 15th. DZ Bank upgraded AbbVie from a "hold" rating to a "strong-buy" rating in a report on Thursday, April 30th. UBS Group increased their price objective on AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a report on Monday, July 13th. Finally, Piper Sandler reissued an "overweight" rating and set a $298.00 price objective on shares of AbbVie in a research report on Tuesday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $275.73.

AbbVie Stock Up 0.4%

ABBV stock opened at $250.53 on Tuesday. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $267.47. The firm has a market cap of $442.63 billion, a PE ratio of 70.77, a price-to-earnings-growth ratio of 0.83 and a beta of 0.30. The business has a 50 day moving average of $245.49 and a 200 day moving average of $226.35.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same quarter in the previous year, the business earned $2.97 earnings per share. The firm's quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts expect that AbbVie Inc. will post 14.07 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's payout ratio is currently 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source